Veru Inc

Company Profile

• Business description

  Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

• Contact

  2916 North Miami Avenue
  Suite 1000
  MiamiFL33127
  USA

  T: +1 305 509-6897

  E: [email protected]

  https://www.verupharma.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  30 September 2026

  Employees

  20